NZ727659A - Residence structures and related methods - Google Patents

Residence structures and related methods

Info

Publication number
NZ727659A
NZ727659A NZ727659A NZ72765915A NZ727659A NZ 727659 A NZ727659 A NZ 727659A NZ 727659 A NZ727659 A NZ 727659A NZ 72765915 A NZ72765915 A NZ 72765915A NZ 727659 A NZ727659 A NZ 727659A
Authority
NZ
New Zealand
Prior art keywords
gastric
polymeric component
active substance
residence structure
shape
Prior art date
Application number
NZ727659A
Other languages
English (en)
Inventor
Robert Langer
Andrew Bellinger
Shiyi Zhang
Carlo Traverso
Stacy Mo
Tyler Grant
Mousa Jafari
Dean Glettig
Angela Diciccio
Lowell Wood
Philip Eckhoff
Original Assignee
Massachusetts Inst Technology
The Brigham And Women’S Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54834353&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ727659(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Massachusetts Inst Technology, The Brigham And Women’S Hospital Inc filed Critical Massachusetts Inst Technology
Publication of NZ727659A publication Critical patent/NZ727659A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
    • A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
    • C08G18/40—High-molecular-weight compounds
    • C08G18/42—Polycondensates having carboxylic or carbonic ester groups in the main chain
    • C08G18/4266—Polycondensates having carboxylic or carbonic ester groups in the main chain prepared from hydroxycarboxylic acids and/or lactones
    • C08G18/4269—Lactones
    • C08G18/4277—Caprolactone and/or substituted caprolactone
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G18/00—Polymeric products of isocyanates or isothiocyanates
    • C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
    • C08G18/70—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the isocyanates or isothiocyanates used
    • C08G18/72—Polyisocyanates or polyisothiocyanates
    • C08G18/73—Polyisocyanates or polyisothiocyanates acyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08—Lactones or lactides
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
    • C08G83/002—Dendritic macromolecules
    • C08G83/005—Hyperbranched macromolecules
    • C08G83/006—After treatment of hyperbranched macromolecules
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/02—Homopolymers or copolymers of acids; Metal or ammonium salts thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/06—Homopolymers or copolymers of esters of esters containing only carbon, hydrogen and oxygen, which oxygen atoms are present only as part of the carboxyl radical
    • C08L33/08—Homopolymers or copolymers of acrylic acid esters
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L33/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides or nitriles thereof; Compositions of derivatives of such polymers
    • C08L33/04—Homopolymers or copolymers of esters
    • C08L33/14—Homopolymers or copolymers of esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2230/00—Compositions for preparing biodegradable polymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Prostheses (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
NZ727659A 2014-06-11 2015-06-11 Residence structures and related methods NZ727659A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462010992P 2014-06-11 2014-06-11
PCT/US2015/035423 WO2015191920A1 (en) 2014-06-11 2015-06-11 Residence structures and related methods

Publications (1)

Publication Number Publication Date
NZ727659A true NZ727659A (en) 2021-12-24

Family

ID=54834353

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ727659A NZ727659A (en) 2014-06-11 2015-06-11 Residence structures and related methods

Country Status (19)

Country Link
US (16) US10413507B2 (enExample)
EP (5) EP4516322A3 (enExample)
JP (9) JP6666858B2 (enExample)
KR (2) KR102471095B1 (enExample)
CN (4) CN106714893B (enExample)
AU (6) AU2015274456B2 (enExample)
BR (2) BR112016028957B1 (enExample)
CA (3) CA2951902C (enExample)
DK (2) DK3155024T4 (enExample)
ES (2) ES3001020T3 (enExample)
FI (2) FI3155024T4 (enExample)
IL (1) IL249435B (enExample)
MX (2) MX2016016406A (enExample)
NZ (1) NZ727659A (enExample)
PL (1) PL3725357T3 (enExample)
RU (1) RU2766335C2 (enExample)
SG (2) SG11201610246PA (enExample)
WO (3) WO2015191925A1 (enExample)
ZA (1) ZA201608889B (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103948557A (zh) 2014-04-08 2014-07-30 闻晓光 一种新型控释片
AU2015271808A1 (en) 2014-06-02 2016-12-08 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US10413507B2 (en) 2014-06-11 2019-09-17 Massachusetts Institute Of Technology Enteric elastomers
CA2964900C (en) 2014-09-25 2023-02-21 Progenity, Inc. Electromechanical pill device with localization capabilities
US10953208B2 (en) 2015-05-01 2021-03-23 Massachusetts Institute Of Technology Triggerable shape memory induction devices
EP3153137A1 (en) * 2015-10-06 2017-04-12 Li Galli B.V. Vaginal drug delivery device and vaginal diagnostic device
US10939865B2 (en) * 2015-10-06 2021-03-09 Ligalli B.V. Vaginal drug delivery device and vaginal diagnostic device
CA3002916C (en) * 2015-10-23 2024-06-11 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
US11147766B2 (en) * 2015-12-01 2021-10-19 Clexio Biosciences Ltd. Gastric retentive devices
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
EP3393537B1 (en) 2015-12-22 2024-05-22 Access Vascular, Inc. High strength biomedical materials
WO2017185003A1 (en) * 2016-04-21 2017-10-26 Massachusetts Institute Of Technology Origami robots and systems
AU2017268840B2 (en) * 2016-05-27 2022-02-10 Nortiva Bio, Inc. Materials architecture for gastric residence systems
IL297016B2 (en) 2016-09-09 2024-01-01 Biora Therapeutics Inc Electromechanical ingestible device for delivery of a dispensable substance
US11576866B2 (en) * 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP3320898A1 (en) 2016-11-11 2018-05-16 ratiopharm GmbH Dosage form comprising a carrier structure and method for manufacturing the dosage form
IL266377B2 (en) * 2016-12-02 2023-10-01 Clexio Biosciences Ltd Gastric residence system
JP2020513554A (ja) 2016-12-07 2020-05-14 プロジェニティ， インコーポレイテッド 胃腸管の検出方法、装置およびシステム
EP3597258B1 (en) * 2017-03-16 2025-09-03 Terumo Kabushiki Kaisha Catheter assembly
AU2018243312B2 (en) 2017-03-31 2023-02-02 Bt Bidco, Inc. Localization systems and methods for an ingestible device
EP3624778A4 (en) * 2017-05-17 2021-03-10 Massachusetts Institute of Technology SELF-FIRING ARTICLES
US11541015B2 (en) 2017-05-17 2023-01-03 Massachusetts Institute Of Technology Self-righting systems, methods, and related components
WO2018227147A1 (en) * 2017-06-09 2018-12-13 Lyndra, Inc. Gastric residence systems with release rate-modulating films
CA3067850A1 (en) 2017-06-21 2018-12-27 Access Vascular, Inc High strength porous materials incorporating water soluble polymers
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
CN107773554A (zh) * 2017-09-07 2018-03-09 华南农业大学 一种伊维菌素缓释微囊及其制备方法和应用
CN111511338B (zh) * 2017-09-20 2022-11-29 林德拉治疗公司 胃驻留系统的封装
WO2019083483A2 (en) * 2017-10-11 2019-05-02 Ege Universitesi A vaginal implant
TWI837082B (zh) * 2017-11-22 2024-04-01 美商萊恩卓治療公司 用於胃滯留系統之材料架構
JP7394775B2 (ja) * 2017-11-28 2023-12-08 マサチューセッツ インスティテュート オブ テクノロジー 胃滞在電子機器
JP7296084B2 (ja) * 2017-12-04 2023-06-22 クレキシオ バイオサイエンシーズ エルティーディー． 長時間作用型胃滞留システム
WO2019222570A1 (en) 2018-05-17 2019-11-21 Massachusetts Institute Of Technology Systems for electrical stimulation
WO2019232296A1 (en) * 2018-05-31 2019-12-05 Massachusetts Institute Of Technology Retrieval systems and related methods
EP3836866A4 (en) * 2018-08-15 2022-06-15 Lyndra Therapeutics, Inc. SYSTEMS FOR ENTERIC DELIVERY OF THERAPEUTICS
AU2019380225A1 (en) * 2018-11-15 2020-11-26 Massachusetts Institute Of Technology Actuating components and related methods
US11648381B2 (en) 2018-11-15 2023-05-16 Massachusetts Institute Of Technology Thermally controlled residence devices
US20220008701A1 (en) * 2018-11-15 2022-01-13 Massachusetts Institute Of Technology Millineedle systems for esophageal drug delivery
CA3120619A1 (en) * 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020117855A1 (en) 2018-12-03 2020-06-11 Lyndra, Inc. Stomach simulating device
WO2020132065A2 (en) 2018-12-19 2020-06-25 Access Vascular, Inc. High strength porous materials for controlled release
JP2022523121A (ja) 2019-02-01 2022-04-21 マサチューセッツ インスティテュート オブ テクノロジー 液体注入のためのシステムおよび方法
US20220192995A1 (en) * 2019-03-20 2022-06-23 Lyndra Therapeutics, Inc. Coatings for gastric residence dosage forms
CN113966216A (zh) * 2019-03-20 2022-01-21 林德拉治疗公司 用于胃滞留剂型的胶囊和胶囊衣层
WO2020257017A1 (en) * 2019-06-18 2020-12-24 Progenity, Inc. Ingestible device with component capable of residing in the gastrointestinal tract
CN110591125B (zh) * 2019-07-31 2021-01-26 北京理工大学 一种可溶解的三维交联弹性体及其制备和处理方法
WO2021067488A1 (en) * 2019-10-01 2021-04-08 Incube Labs, Llc Self-sizing device for delivering a formulation to a lumen wall
CN115003335A (zh) * 2019-11-08 2022-09-02 林德拉治疗公司 用于施用活性剂的胃驻留系统
WO2021092484A1 (en) * 2019-11-08 2021-05-14 Lyndra, Inc. Gastric residence systems having arms with controlled stiffness for improved gastric residence
WO2021092487A1 (en) * 2019-11-08 2021-05-14 Lyndra, Inc. Polymeric linkers for a gastric residence system
EP4054642A4 (en) * 2019-11-08 2024-02-28 Lyndra Therapeutics, Inc. Formulations for release-rate modulating films for gastric residence systems
US20220409528A1 (en) * 2019-11-08 2022-12-29 Lyndra Therapeutics, Inc. Gastric residence systems having a filament for improved gastric residence
US11541216B2 (en) 2019-11-21 2023-01-03 Massachusetts Institute Of Technology Methods for manufacturing tissue interfacing components
EP4309722A3 (en) 2019-12-13 2024-08-07 Biora Therapeutics, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
WO2021178785A1 (en) * 2020-03-06 2021-09-10 Access Vascular, Inc. Packaging for hydrated articles and related methods
US11253534B2 (en) 2020-03-23 2022-02-22 Sabine Hazan Method of preventing COVID-19 infection
US11744866B2 (en) 2020-03-18 2023-09-05 Sabine Hazan Methods of preventing and treating COVID-19 infection with probiotics
US11278520B2 (en) 2020-03-31 2022-03-22 Sabine Hazan Method of preventing COVID-19 infection
WO2021231411A1 (en) * 2020-05-12 2021-11-18 Massachusetts Institute Of Technology Gastroretentive articles for alcohol sensing
CN115989054A (zh) 2020-06-30 2023-04-18 阿塞斯血管有限公司 包含标记的制品和相关方法
CN116234540A (zh) * 2020-07-29 2023-06-06 赛康特集团有限责任公司 具有包括交联聚(癸二酸甘油酯)的结构的形状引导控释和滞留
JP2024518156A (ja) * 2021-05-05 2024-04-25 リンドラ セラピューティクス， インコーポレイティド ブプレノルフィンとナロキソンを含む胃内滞留システム
WO2023021480A1 (en) 2021-08-19 2023-02-23 Clexio Biosciences Ltd. Method of treating parkinson's disease
AU2023354428A1 (en) * 2022-09-30 2025-04-17 Nortiva Bio, Inc. Risperidone dosage regimens with gastric residence systems
WO2024081793A1 (en) 2022-10-12 2024-04-18 Massachusetts Institute Of Technology Ingestible in vivo-assembling drug release formulations and methods
US20240398701A1 (en) * 2023-06-02 2024-12-05 Lyndra Therapeutics, Inc. Manufacturing methods for gastric residence systems
WO2025090468A1 (en) * 2023-10-24 2025-05-01 Soane Pharma LLC Orally ingestible delivery system
CN119971273A (zh) * 2024-01-09 2025-05-13 厦门君德医药科技有限公司 一种胃滞留装置
KR20250121713A (ko) * 2024-02-05 2025-08-12 재단법인대구경북과학기술원 장내 생물학적 물질 다중 채취를 위한 채취 모듈 전달 캡슐
US20250295901A1 (en) * 2024-03-19 2025-09-25 Lyndra Therapeutics, Inc. Flexible line configurations for gastric residence systems
CN120154807B (zh) * 2024-03-22 2025-11-21 厦门君德医药科技有限公司 一种胃滞留装置
WO2025222033A1 (en) * 2024-04-18 2025-10-23 The Regents Of The University Of California Time-controlled payload release capsules

Family Cites Families (137)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US415671A (en) * 1889-11-19 harris
US3154461A (en) 1960-03-07 1964-10-27 Minnesota Mining & Mfg Matte-finish polymeric film and method of forming the same
AU449029B2 (en) 1969-08-28 1974-04-17 Commonwealth Scientific And Industrial Research Organisation Device for administration to ruminants
JPS5512411B2 (enExample) 1974-03-12 1980-04-02
US4199561A (en) * 1979-02-26 1980-04-22 The Dow Chemical Company Coated nutrients and medicaments for veterinary use
US4451260A (en) 1982-03-26 1984-05-29 Minnesota Mining And Manufacturing Company Sustained release oral medicinal delivery device
US4676507A (en) 1985-05-06 1987-06-30 Patterson Bruce D Puzzles forming platonic solids
US4735804A (en) 1985-05-10 1988-04-05 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
JPS6226215A (ja) * 1985-05-10 1987-02-04 メルク　エンド　カムパニ−　インコ−ポレ−テツド 一定に制御した時間内胃中に保持できる薬剤移送装置
EP0202159B1 (en) * 1985-05-10 1991-07-03 Merck & Co. Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4767627A (en) 1985-05-29 1988-08-30 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
US4758436A (en) 1985-05-29 1988-07-19 Merck & Co., Inc. Drug delivery device which can be retained in the stomach for a controlled period of time
EP0253554A3 (en) * 1986-07-15 1988-07-20 Pfizer Inc. Controlled release drug-containing fibers
IL87710A (en) 1987-09-18 1992-06-21 Ciba Geigy Ag Covered floating retard form for controlled release in gastric juice
EP0406315B1 (en) 1988-03-24 1992-11-11 Bukh Meditec A/S Controlled release composition
US5002772A (en) 1988-05-31 1991-03-26 Pfizer Inc. Gastric retention system for controlled drug release
NZ228382A (en) * 1989-03-17 1992-08-26 Carter Holt Harvey Plastic Pro Drug administering coil-like device for insertion in body cavity of animal
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
JPH03163011A (ja) 1989-08-31 1991-07-15 Yamanouchi Pharmaceut Co Ltd 胃内滞留デバイス
US5047464A (en) * 1989-09-20 1991-09-10 Merck & Co., Inc. Bioerodible thermoset elastomers
US5369142A (en) * 1993-01-15 1994-11-29 The Ohio State University Water soluble polymers containing amino acid residues for dental restoratives
WO1995003558A1 (en) * 1993-07-19 1995-02-02 Reflexite Corporation Retroreflective structure
DE4406424A1 (de) 1994-02-28 1995-08-31 Bayer Ag Expandierbare Arzneiformen
DE69624227T2 (de) 1995-03-23 2003-06-12 Advanced Animal Technology Ltd., Hamilton Substanzabgabevorrichtung
US6962579B2 (en) 1995-03-23 2005-11-08 Advanced Animal Technology Limited Substance delivery device
TW354451B (en) 1995-09-18 1999-03-11 Ibm Method of fabricating cross-linked biobased materials and structures fabricated therewith a method comprising the step of: forming the mixture of polymer and cross-linked agent
US5840332A (en) 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
AU2521797A (en) 1996-04-12 1997-11-07 Japan Atomic Energy Research Institute Ph-sensitive polymers
GB9616267D0 (en) 1996-08-02 1996-09-11 Ranier Ltd Balloon catheter
JP2001527023A (ja) 1997-08-11 2001-12-25 アルザ・コーポレーション 胃で保持するのに適合した長期放出性活性剤剤形
DE19850309A1 (de) 1998-10-30 2000-05-04 Lohmann Therapie Syst Lts Expandierbares gastroretensives Therapiesystem mit verlängerter Magenverweildauer
IL133196A0 (en) 1999-11-29 2001-03-19 Yissum Res Dev Co Gastroretentive controlled release pharmaceutical dosage forms
WO2001091553A1 (en) 2000-05-26 2001-12-06 Demegen, Inc. Composite wafer for controlled drug delivery
US6488962B1 (en) 2000-06-20 2002-12-03 Depomed, Inc. Tablet shapes to enhance gastric retention of swellable controlled-release oral dosage forms
US8158143B2 (en) 2000-07-14 2012-04-17 Helmholtz-Zentrum Geesthacht Zentrum Fuer Material- Und Kuestenforschung Gmbh Systems for releasing active ingredients, based on biodegradable or biocompatible polymers with a shape memory effect
US7803392B2 (en) 2000-12-27 2010-09-28 University Of Kentucky Research Foundation pH-Sensitive mucoadhesive film-forming gels and wax-film composites suitable for topical and mucosal delivery of molecules
US6627206B2 (en) 2001-07-25 2003-09-30 Greg A. Lloyd Method and apparatus for treating obesity and for delivering time-released medicaments
US20040219186A1 (en) 2001-08-16 2004-11-04 Ayres James W. Expandable gastric retention device
CN1543337A (zh) 2001-08-16 2004-11-03 ���ո����ɸߵȽ�����ίԱ�������� 可膨胀的胃潴留装置
US20030152622A1 (en) * 2001-10-25 2003-08-14 Jenny Louie-Helm Formulation of an erodible, gastric retentive oral diuretic
CA2409552A1 (en) * 2001-10-25 2003-04-25 Depomed, Inc. Gastric retentive oral dosage form with restricted drug release in the lower gastrointestinal tract
KR100417163B1 (ko) 2001-11-12 2004-02-05 한국과학기술연구원 마이크로 캡슐형 로봇
US20050165136A1 (en) * 2002-01-23 2005-07-28 Uab Research Foundation Glass-ionomer cements containing amino acids
AU2003234159A1 (en) * 2002-04-22 2003-11-03 Purdue Research Foundation Hydrogels having enhanced elasticity and mechanical strength properties
DE10224352A1 (de) 2002-06-01 2003-12-11 Mueller Schulte Detlef Thermosensitive Polymerträger mit veränderbarer physikalischer Struktur für die biochemische Analytik, Diagnostik und Therapie
GB0214013D0 (en) 2002-06-18 2002-07-31 Euro Celtique Sa Pharmaceutical product
TWI336260B (en) 2002-07-25 2011-01-21 Glaxo Group Ltd Dosage form suitable for retaining drug substance
CA2501345A1 (en) 2002-10-11 2004-04-22 Depomed Development, Ltd. Gastro-retentive levodopa delivery form
CA2516285A1 (en) * 2003-02-19 2004-09-02 Mnemoscience Gmbh Self-expanding device for the gastrointestinal or urogenital area
JP4497833B2 (ja) 2003-04-21 2010-07-07 富士フイルム株式会社 ポジ型平版印刷版原版
US7662864B2 (en) * 2003-06-04 2010-02-16 Rutgers, The State University Of New Jersey Solution polymerization processes to prepare a polymer that degrades to release a physiologically active agent
BRPI0411437B8 (pt) 2003-06-13 2021-06-22 Gkss Forschungszentrum Geesthacht Gmbh stent para uso no campo não-vascular ou vascular, método para sua fabricação e kit compreendendo esse stent
EP1638533A1 (en) 2003-06-18 2006-03-29 John Michael Newton Controlled release devices with lumens
US8048169B2 (en) * 2003-07-28 2011-11-01 Baronova, Inc. Pyloric valve obstructing devices and methods
US20090259236A2 (en) 2003-07-28 2009-10-15 Baronova, Inc. Gastric retaining devices and methods
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US6825308B1 (en) * 2003-10-29 2004-11-30 Council Of Scientific And Industrial Research Copolymers and preparation thereof
WO2005056708A2 (en) 2003-12-09 2005-06-23 Spherics, Inc. Bioadhesive polymers with catechol functionality
US20080089933A1 (en) 2006-10-16 2008-04-17 Amir Alon Device and method for reducing calorie intake
CA2567741A1 (en) * 2004-05-25 2006-03-30 Chimeracore, Inc. Self-assembling nanoparticle drug delivery system
DE102004047076A1 (de) 2004-09-28 2006-04-06 Zimmer Ag Verfahren zur Herstellung von Polyestern
IL166183A0 (en) 2005-01-06 2006-01-15 Yissum Res Dev Co Novel diagnostic and imaging techniques of the gi tract
RU2411045C2 (ru) * 2005-01-27 2011-02-10 Институт Нефтехимического Синтеза Имени А.В. Топчиева Ран Гидрофильные биологически совместимые адгезивные композиции и их применение
US20080153779A1 (en) 2005-02-01 2008-06-26 Jun Liao Gastric Retention and Controlled Release Delivery System
US7785291B2 (en) 2005-03-01 2010-08-31 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
US7699863B2 (en) * 2005-03-01 2010-04-20 Tulip Medical Ltd. Bioerodible self-deployable intragastric implants
JP2006323082A (ja) 2005-05-18 2006-11-30 Canon Inc 現像剤補給容器
US8021384B2 (en) 2005-07-26 2011-09-20 Ram Weiss Extending intrabody capsule
US20090120879A1 (en) 2005-08-05 2009-05-14 Shiga Prefecture Material For Transfer Of Substance In Liquid Comprising Polymer Blend
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
EP1957052A2 (en) 2005-10-25 2008-08-20 Pharmascience Inc. A gastric retention drug delivery system
EP1945189A4 (en) * 2005-11-03 2012-08-15 Sun Pharmaceutical Ind Ltd CONTROLLED RELEASE COATED TABLETS CHARACTERIZED BY PROLONGED GASTRIC RETENTION
US7674396B2 (en) 2005-11-08 2010-03-09 Plensat Llc Method and system for treatment of eating disorders
JP5399715B2 (ja) 2006-01-18 2014-01-29 インテック ファーマ リミテッド 薬剤の経口摂取用の送達デバイスを形成する方法および装置
WO2007093999A1 (en) 2006-02-15 2007-08-23 Intec Pharma Ltd. A gastro-retentive system for the delivery of macromolecules
US20090246142A1 (en) * 2006-03-10 2009-10-01 Massachusetts Institute Of Technology Triggered Self-Assembly of Nanoparticles In Vivo
US7691151B2 (en) 2006-03-31 2010-04-06 Spiration, Inc. Articulable Anchor
US20070264307A1 (en) 2006-05-15 2007-11-15 Medtronic Vascular, Inc. Biodegradable Modified Caprolactone Polymers for Fabricating and Coating Medical Devices
EP1886665A1 (en) 2006-08-01 2008-02-13 Boehringer Ingelheim Pharma GmbH & Co. KG Gastro retentive delivery system
KR20090065524A (ko) 2006-09-04 2009-06-22 파나세아 바이오테크 리미티드 프로그래머블 부력전달기술
US20080075766A1 (en) 2006-09-25 2008-03-27 Shun-Por Li Multi-core dosage form having transparent outer coating
US20100316712A1 (en) 2006-12-22 2010-12-16 Combinatorx, Incorporated Pharmaceutical compositions for treatment of parkinson's disease and related disorders
WO2008140651A2 (en) 2007-03-13 2008-11-20 Olson Arthur J Self-assembled polyhedra
WO2008111077A2 (en) * 2007-03-13 2008-09-18 Technion Research & Development Foundation Ltd. Self-assembled polyhedral multimeric chemical structures
US20080249156A1 (en) * 2007-04-09 2008-10-09 Palepu Nageswara R Combinations of statins and anti-obesity agent and glitazones
CA2687979C (en) 2007-05-25 2017-07-04 Tolmar Therapeutics, Inc. Sustained delivery formulations of risperidone compounds
WO2008148083A1 (en) * 2007-05-25 2008-12-04 Gorham Enterprises Llc Bariatric magnetic apparatus and method of manufacturing thereof
US8038659B2 (en) * 2007-10-17 2011-10-18 The Invention Science Fund I, Llc Disintegrating digestive tract interaction system
US8303573B2 (en) * 2007-10-17 2012-11-06 The Invention Science Fund I, Llc Medical or veterinary digestive tract utilization systems and methods
AU2009223061B2 (en) 2008-03-11 2014-10-09 Depomed Inc. Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US20130273135A1 (en) 2008-03-25 2013-10-17 University Of Utah Research Foundation Controlled Release Combination Biomaterials
LT2276473T (lt) 2008-04-18 2017-02-27 Intec Pharma Ltd. Pailginto atpalaidavimo vaistų karbidopa/levodopa įvedimas
EP2280670A4 (en) * 2008-04-28 2012-08-01 Eatlittle Inc BÉZOARD TRAINING UNITS FOR WEIGHT CONTROL
US20100256342A1 (en) * 2008-08-12 2010-10-07 Francis Raymond Salemme Protein nodes for controlled nanoscale assembly
EP2329810A4 (en) 2008-08-18 2012-09-19 Team Academy Of Pharmaceutical Science DRUG DISPENSING SYSTEM WITH MAGNETIC RETENTION, MANUFACTURING PROCESS AND APPLICATION
PL2349222T3 (pl) 2008-09-10 2017-08-31 Sandoz Ag Kapsułka z rozpuszczalnym elementem blokującym
US20110268666A1 (en) 2008-09-29 2011-11-03 Yissum Research Development Company of the Research University of Jerusalem, Ltd. Novel gastroretentive delivery system
KR20110116004A (ko) 2008-12-04 2011-10-24 인텍 파마 리미티드 잘레플론 위장체류 약물 전달 시스템
WO2010074712A2 (en) * 2008-12-27 2010-07-01 Duggirala Chandra S Devices for treating obesity and methods of using those devices
WO2010099466A2 (en) 2009-02-26 2010-09-02 The Regents Of The University Of California A supramolecular approach for preparation of size controllable nanoparticles
US8414559B2 (en) 2009-05-07 2013-04-09 Rainbow Medical Ltd. Gastroretentive duodenal pill
DE102009028076A1 (de) 2009-07-29 2011-02-03 Evonik Röhm Gmbh Beschichtungsmittel zum Tauchbeschichten von Kapselhälften
US20110052497A1 (en) * 2009-08-27 2011-03-03 Taris Biomedical, Inc. Minimally Invasive Systems and Methods for In Vivo Testing of Materials
US20110052700A1 (en) 2009-08-31 2011-03-03 Depomed, Inc. Gastric retentive pharmaceutical compositions for immediate and extended release of levosulpiride
WO2011032087A2 (en) 2009-09-11 2011-03-17 Replication Medical Inc. Swellable polymeric device for dietary regulation
WO2011048494A2 (en) 2009-10-19 2011-04-28 Intec Pharma Ltd. Novel gastroretentive dosage forms of poorly soluble drugs
US9421169B2 (en) * 2009-11-20 2016-08-23 Covidien Lp Oral dosage forms for delivery of therapeutic agents
CN101711752B (zh) 2009-11-26 2011-09-21 中国科学院上海药物研究所 一种苯并异噁唑类衍生物的控释制剂及其制备方法
FI3756657T3 (fi) * 2009-12-24 2025-05-30 Rani Therapeutics Llc Nieltävä lääkkeenantolaite
CA2796435C (en) * 2010-04-15 2019-05-07 The Washington University Prodrug compositions, prodrug nanoparticles, and methods of use thereof
US11535510B2 (en) * 2010-04-27 2022-12-27 The Johns Hopkins University Self-folding sub-centimeter structures
BRPI1002601E2 (pt) * 2010-06-01 2020-06-30 Embrapa Pesquisa Agropecuaria composição nanoestruturada de uso veterinário para administração de fármacos
US20120165793A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165792A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
US20120165794A1 (en) 2010-12-22 2012-06-28 Ethicon Endo-Surgery, Inc. Pill Catchers
WO2012106714A1 (en) 2011-02-04 2012-08-09 Taris Biomedical, Inc. Implantable device for controlled release of low solubility drug
JP2014533975A (ja) * 2011-09-26 2014-12-18 ノースイースタン・ユニバーシティ カスタマイズ可能な埋め込みセンサ
US8835507B2 (en) 2012-02-21 2014-09-16 Vymed Corporation Adamantane derivatives possessing anti-viral and anti-microbial activity
US8979887B2 (en) 2012-02-24 2015-03-17 Elwha Llc Devices, systems, and methods to control stomach volume
MX2015000760A (es) 2012-07-16 2015-09-10 Apet Holding B V Sistema de suministro de farmaco gastro - retentivo.
US9307966B2 (en) 2012-08-15 2016-04-12 St. Jude Medical Puerto Rico Llc Vascular closure device anchor
IN2015DN01023A (enExample) 2012-08-16 2015-06-26 Teva Pharma
US8746339B2 (en) * 2012-09-27 2014-06-10 Halliburton Energy Services, Inc. Triggerable lost circulation material and method of use
US10441760B2 (en) 2013-03-01 2019-10-15 The Johns Hopkins University Self-actuating chemomechanical devices for delivery and extended release of therapeutic agents in the gastrointestinal tract
CN103654903A (zh) * 2013-11-27 2014-03-26 西安交通大学 一种用于人体消化道吻合的磁性可降解装置
EP3091962B1 (en) 2013-12-05 2022-06-08 Epitomee Medical Ltd. Retentive devices and systems for in-situ release of pharmaceutical active agents
WO2015168297A1 (en) 2014-04-29 2015-11-05 Massachusetts Institute Of Technology Polymeric materials for bio-applications
US9872835B2 (en) 2014-05-26 2018-01-23 Grünenthal GmbH Multiparticles safeguarded against ethanolic dose-dumping
AU2015271808A1 (en) 2014-06-02 2016-12-08 Clexio Biosciences Ltd. Expandable gastroretentive dosage form
US20170266112A1 (en) 2014-06-11 2017-09-21 Massachusetts Institute Of Technology Residence structures and related methods
US10413507B2 (en) 2014-06-11 2019-09-17 Massachusetts Institute Of Technology Enteric elastomers
US10953208B2 (en) 2015-05-01 2021-03-23 Massachusetts Institute Of Technology Triggerable shape memory induction devices
CA3002916C (en) 2015-10-23 2024-06-11 Lyndra, Inc. Gastric residence systems for sustained release of therapeutic agents and methods of use thereof
KR102796240B1 (ko) 2015-12-08 2025-04-16 린드라 테라퓨틱스 인코퍼레이티드 위 체류 시스템을 위한 기하 구성형태
AU2017268840B2 (en) 2016-05-27 2022-02-10 Nortiva Bio, Inc. Materials architecture for gastric residence systems
US11576866B2 (en) 2016-09-30 2023-02-14 Lyndra Therapeutics, Inc. Gastric residence systems for sustained delivery of adamantane-class drugs
EP4281049A4 (en) * 2021-01-19 2025-04-23 Lyndra Therapeutics, Inc. GASTRIC RESIDENCE SYSTEMS FOR RISPERIDONE DELIVERY

Also Published As

Publication number Publication date
KR102471095B1 (ko) 2022-11-28
JP2020097623A (ja) 2020-06-25
EP3154622B1 (en) 2020-04-01
CN116370644A (zh) 2023-07-04
US10716752B2 (en) 2020-07-21
EP3725357A1 (en) 2020-10-21
SG11201610246PA (en) 2017-01-27
CA2951884A1 (en) 2015-12-17
EP3154553A4 (en) 2018-03-28
WO2015191925A1 (en) 2015-12-17
EP4516322A2 (en) 2025-03-05
AU2021203086B2 (en) 2023-02-23
ES3001020T3 (es) 2025-03-04
ES2832334T3 (es) 2021-06-10
JP2022031924A (ja) 2022-02-22
EP3155024A1 (en) 2017-04-19
ES2832334T5 (en) 2025-09-24
JP2017524662A (ja) 2017-08-31
US20170128576A1 (en) 2017-05-11
EP3725357B1 (en) 2024-11-13
JP6681390B2 (ja) 2020-04-15
EP3154553A1 (en) 2017-04-19
US20190070107A1 (en) 2019-03-07
SG10201912100SA (en) 2020-02-27
AU2015274451C1 (en) 2019-09-12
MX2016016406A (es) 2017-10-12
CN106714893A (zh) 2017-05-24
JP2020056042A (ja) 2020-04-09
WO2015191925A8 (en) 2016-02-11
EP3155024A4 (en) 2018-01-17
AU2020200346A1 (en) 2020-02-06
PL3725357T3 (pl) 2025-03-03
CN106714893B (zh) 2021-01-01
FI3155024T4 (fi) 2025-07-28
IL249435A0 (en) 2017-02-28
BR112016028957B1 (pt) 2021-12-14
JP2017519098A (ja) 2017-07-13
JP2020114874A (ja) 2020-07-30
US11083690B2 (en) 2021-08-10
KR20170016960A (ko) 2017-02-14
CA2951909A1 (en) 2015-12-17
JP7337746B2 (ja) 2023-09-04
EP3155024B2 (en) 2025-06-18
CA2951909C (en) 2022-08-16
US11389399B2 (en) 2022-07-19
WO2015191920A1 (en) 2015-12-17
EP3154622A1 (en) 2017-04-19
KR102704895B1 (ko) 2024-09-11
BR112016028957A2 (pt) 2017-08-22
US10849853B2 (en) 2020-12-01
AU2020200346B2 (en) 2021-08-05
EP3154553B1 (en) 2020-08-05
US20200085736A1 (en) 2020-03-19
EP4516322A3 (en) 2025-05-14
AU2015274453A2 (en) 2017-01-19
US20190298652A1 (en) 2019-10-03
US20200085737A1 (en) 2020-03-19
EP3154622A4 (en) 2018-01-17
US20190175500A1 (en) 2019-06-13
CA2951902C (en) 2022-08-23
KR20220162852A (ko) 2022-12-08
AU2015274451A1 (en) 2017-01-12
AU2019232862A1 (en) 2019-10-10
US11357723B2 (en) 2022-06-14
US10517820B2 (en) 2019-12-31
JP6666858B2 (ja) 2020-03-18
CN106573999A (zh) 2017-04-19
US10532027B2 (en) 2020-01-14
US20210177750A1 (en) 2021-06-17
US20170135954A1 (en) 2017-05-18
US11246829B2 (en) 2022-02-15
RU2017100273A3 (enExample) 2018-11-12
US11077056B2 (en) 2021-08-03
ZA201608889B (en) 2022-04-28
JP2023022316A (ja) 2023-02-14
AU2015274456B2 (en) 2020-03-26
US20230039421A1 (en) 2023-02-09
EP3155024B1 (en) 2020-09-16
DK3725357T3 (da) 2024-12-09
JP7629898B2 (ja) 2025-02-14
JP7405820B2 (ja) 2023-12-26
CN106573015A (zh) 2017-04-19
US10716751B2 (en) 2020-07-21
RU2017100273A (ru) 2018-07-11
JP2017519003A (ja) 2017-07-13
CN106573015B (zh) 2021-11-26
RU2766335C2 (ru) 2022-03-15
WO2015191922A1 (en) 2015-12-17
IL249435B (en) 2020-08-31
US20210128460A1 (en) 2021-05-06
MX2023005223A (es) 2023-05-16
US10517819B2 (en) 2019-12-31
JP2025041821A (ja) 2025-03-26
US20200030234A1 (en) 2020-01-30
US20190070108A1 (en) 2019-03-07
AU2015274451B2 (en) 2019-06-20
DK3155024T3 (da) 2020-11-23
US20210093564A1 (en) 2021-04-01
CA2951902A1 (en) 2015-12-17
AU2015274456A1 (en) 2017-01-12
WO2015191920A8 (en) 2016-02-04
BR122021018078B1 (pt) 2022-02-08
EP4516322A8 (en) 2025-04-16
AU2021203086A1 (en) 2021-06-10
FI3725357T3 (fi) 2024-12-13
US10182985B2 (en) 2019-01-22
AU2015274453A1 (en) 2017-01-12
US20210113460A1 (en) 2021-04-22
US20170106099A1 (en) 2017-04-20
US10610482B2 (en) 2020-04-07
US20190133936A1 (en) 2019-05-09
US10413507B2 (en) 2019-09-17
DK3155024T4 (da) 2025-07-21

Similar Documents

Publication Publication Date Title
NZ727659A (en) Residence structures and related methods
Jiang et al. Chitosan as a biomaterial: structure, properties, and applications in tissue engineering and drug delivery
WO2011112229A3 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
EP3316872A4 (en) Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2017091749A8 (en) Shape changing drug delivery devices and methods
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
EA201791702A1 (ru) Терапевтические средства на основе гликанов и связанные с ними способы
RU2016151697A (ru) Расправляемая удерживаемая в желудке лекарственная форма
WO2008124617A3 (en) Rapidly dissolving pharmaceutical compositions comprising pullulan
IN2014CN00338A (enExample)
GT201200217A (es) Derivados de 3-hidroxi-5-arilisotiazol novedosos
EA201690596A1 (ru) Лекарственный препарат с отсроченным высвобождением
MX378264B (es) Sistema para la entrega de polímeros líquidos para la administración prolongada de fármacos.
PL3793534T3 (pl) Tabletka doustna do dostarczania składników czynnych do przewodu żołądkowo-jelitowego
CL2014003148A1 (es) Composición farmacéutica acuosa que contiene un agente terapéutico biológico y guanidina o un derivado de la guanidina y una inyección que incluye la composición.
BR112012028656A2 (pt) combinação de grânulos carregados ativos com ativos adicionais
WO2008141111A3 (en) Polymers conjugated with platinum drugs
JP2017537912A5 (enExample)
EP3294273A4 (en) Anti-interleukin antibody preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
WO2008096606A1 (ja) 管腔通過確認装置および管腔通過確認方法
SG10201807992RA (en) Therapeutic instrument
EA202190565A1 (ru) Пеллеты с многослойной структурой для замедленного высвобождения действующего вещества в дистальных отделах толстой кишки
BR112014032010A2 (pt) regime de dosagem para tratamento animal
PH12016502591B1 (en) Pharmaceutical for treating dizziness having different causes
Bruni-Fitzgerald Review of article: Early cardiopulmonary resuscitation in out-of-hospital cardiac arrest. Hasselqvist-Ax I, Riva G, Herlitz J, Rosenqvist M, et al (N Engl J Med 2015; 374: 2307-2315)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2023 BY COMPUTER PACKAGES INC

Effective date: 20220519

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2024 BY COMPUTER PACKAGES INC

Effective date: 20230518

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2025 BY COMPUTER PACKAGES INC

Effective date: 20240517

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 11 JUN 2026 BY COMPUTER PACKAGES INC

Effective date: 20250517